

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Guangzhou Innogen Pharmaceutical Group Co., Ltd.

廣州銀諾醫藥集團股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 2591)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON CLINICAL TRIAL OF EFSUBAGLUTIDE ALFA
FOR THE TREATMENT OF OBESITY FOR ADOLESCENTS**

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the “**Company**” together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of its recent business updates.

As disclosed in the announcement of the Company dated 22 June 2026, the Company expects to commence Phase Ib clinical trial for the Group’s Efsubaglutide Alfa for treatment of obesity for adolescents in July 2026. The board of directors (the “**Directors**”) of the Company is pleased to announce that on 28 July 2026, the Company successfully completed the first patient enrollment and dosing for Phase Ib of such clinical trial, and no safety concerns or adverse reactions were identified during the observation period.

The Company will continue to update the Shareholders and potential investors on material progress in accordance with applicable regulatory requirements.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop and/or market Efsubaglutide Alfa for the treatment of obesity for adolescents successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People’s Republic of China, 28 July 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.